Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies
NCT00666081 · GlaxoSmithKline · PHASE1 · withdrawn · last registry update 2015-04-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study Cancelled before enrollment” | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AKT2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-04-15Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01425879)
- 2016-03-28Results posted on the registry: Genentech, Inc., Ipatasertib + Cobimetinib (NCT01562275)
- 2016-03-10Also stopped (withdrawn): Dana-Farber Cancer Institute, MK-2206 (NCT01249105)
- 2016-03-09Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 + Fluorouracil (NCT01658943)
- 2016-02-18Results posted on the registry: Memorial Sloan Kettering Cancer Center, MK-2206 (NCT01169649)
- 2016-02-12Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01277757)
- 2015-11-18Also stopped (terminated): Memorial Sloan Kettering Cancer Center, MK-2206 (NCT01186705)
- 2015-11-10Results posted on the registry: National Cancer Institute (NCI), Akt inhibitor MK2206 (NCT01258998)
- 2015-10-05Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01239355)
- 2015-10-05Also stopped (terminated): National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01239355)
- 2015-08-27Also stopped (terminated): National Cancer Institute (NCI), Akt Inhibitor MK2206 + Lapatinib Ditosylate (NCT01281163)
- 2015-06-26Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01604772)
- 2015-04-21Results posted on the registry: Memorial Sloan Kettering Cancer Center, MK-2206 (NCT01186705)
- 2015-01-08Results posted on the registry: National Cancer Institute (NCI), Akt inhibitor MK2206 (NCT01349933)
- 2015-01-07Results posted on the registry: National Cancer Institute (NCI), Akt inhibitor MK2206 (NCT01253447)
- 2014-12-04Results posted on the registry: National Cancer Institute (NCI), MK-2206 + AZD6244 (NCT01333475)
- 2014-09-09Also stopped (withdrawn): National Cancer Institute (NCI), selumetinib + Akt inhibitor MK2206 (NCT01859182)
- 2014-08-04Results posted on the registry: National Cancer Institute (NCI), Akt Inhibitor MK2206 (NCT01260701)
- 2014-07-10Also stopped (terminated): Centre Leon Berard, MK2206 (NCT01466868)
- 2014-06-18Results posted on the registry: National Cancer Institute (NCI), Akt inhibitor MK2206 + selumetinib (NCT01519427)
- 2014-06-18Also stopped (terminated): National Cancer Institute (NCI), Akt inhibitor MK2206 + selumetinib (NCT01519427)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision